Personalized CRISPR Therapies Could Soon Reach Thousands — But How?

A Drug for Every Mutation: Personalized CRISPR Therapies Enter a New Era with the FDA's Plausible Mechanism Pathway

Baby KJ's Story: Six Months That Changed History

A baby born in Philadelphia in February 2025 marked a turning point in medical history. Known as Baby KJ, the child was born with an ultra-rare metabolic disease called carbamoyl phosphate synthetase 1 (CPS1) deficiency . In this disease, the body cannot break down urea, a natural by-product of protein digestion, resulting in the accumulation of toxic ammonia that destroys brain cells. Without treatment, these children face either permanent neurological damage or death. Liver transplantation was the only option, but KJ was too small and too fragile for a transplant operation.

KJ's team took an unconventional approach. Within six months, they developed a base-editing CRISPR therapy designed specifically for the exact mutation in KJ's genome. The treatment was packaged in lipid nanoparticles (LNP — lipid nanoparticle) and administered intravenously. KJ received it at 6–7 months of age. The result: the baby gradually became able to process dietary protein and showed marked clinical improvement. This was the first time in the world that a person had improved following a CRISPR treatment tailored to their own mutation.

Why Did We Have to Conduct a New Clinical Trial for Every Patient?

The operating principle of CRISPR gene editing can be explained with a simple analogy: just as a letter needs the correct address, CRISPR needs an address to find and repair a mutation. That address is a short nucleic acid sequence called guide RNA . A guide RNA is designed for each specific mutation — a different address for each patient.

Under traditional regulatory rules, every different guide RNA is classified as a new drug. This means starting the process from scratch each time:

This process may be reasonable when patients with conditions such as hemophilia or sickle cell anemia can live for years on existing treatments. But the situation is different for severe neonatal metabolic, immune, lung, or skin diseases. For these children, treatment within the first year is vital . An even more painful reality was this: Developing a drug to treat just one child, with an upfront investment of $25 million, was not economically sustainable for any pharmaceutical company. The result: the technology and knowledge exist, but the ecosystem cannot scale these treatments.

The FDA's New Pathway: Approval as a Platform

In November 2025, FDA Commissioner Martin Makary and Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad first presented this new framework in the New England Journal of Medicine. In February 2026, the FDA published its official draft guidance. The central idea is strikingly simple yet radical:

The fundamental innovation of the new approach is to formally recognize the concept of platform technology . It will become possible to treat patients who have different mutations but the same clinical presentation within a single clinical trial using the same CRISPR platform. Thus, a child with CPS1 deficiency, another with ornithine transcarbamylase (OTC) deficiency, and another with argininosuccinic aciduria could all participate in the same trial under the heading of urea cycle disorders.

Four Reforms to Make the New Pathway Truly Work

Urnov and Kassim's commentary in Natureemphasizes that the FDA's step is only a beginning. For this pathway to fulfill its promise, four fundamental updates are needed:

Which Diseases Will Benefit First?

The authors recommend that the FDA initially prioritize disease groups with a clearly high benefit–risk ratio. Severe pediatric immune diseases stand out in particular: Severe pediatric immunodeficiencies caused by mutations in more than 50 genescan cause children to die within 3–6 months after birth. An experimental trial is ethically defensible for these patients because, without treatment, the clinical course is already catastrophic.

What Other Phenotype Groups Stand Out?

Is Everything Really This Simple? A Critical Perspective

Although the Plausible Mechanism Pathway was quickly welcomed as a source of hope, critical voices are also too strong to ignore. Scientific media outlets such as STAT News and C&EN have brought several serious questions raised by this pathway to public attention.

US–China Competition: Why Is Regulatory Speed Critical?

Behind the FDA's move is also concern that the US could lose its leadership in the global gene-therapy race. In recent years, China has increasingly streamlined its regulatory structure to evaluate innovative trials and medicines rapidly. According to many biotechnology analysts, China has caught up with the US, and in some areas surpassed it, particularly in early-stage gene-therapy innovation. The Plausible Mechanism Pathway can also be read as a response to this dynamic: unless the US updates its regulatory structure, early gene-therapy innovation could keep shifting toward Beijing.

What Does This Mean for Turkey?

Turkey's gene-therapy ecosystem is still in its infancy. Although the infrastructure for diagnosing ultra-rare metabolic and immune diseases is well developed, especially in major centers, the manufacturing and regulatory infrastructure required for personalized CRISPR therapies does not yet exist. This FDA initiative will not have a direct short-term impact on Turkey.

Nevertheless, two important long-term outcomes can be anticipated. First, a route could open for children diagnosed with ultra-rare genetic diseases in Turkey to access these treatments at US or European centers, although this would involve substantial costs and organizational requirements. Second, Turkey's academic and medical ecosystem could build its own capacity through international collaboration in this field. How the World Health Organization and other international bodies shape access to these technologies for low- and middle-income countries in the coming years will be a particularly critical issue for Turkey.

This article was created as part of a process using various editorial tools, including artificial intelligence. It was reviewed by human editors before publication.